Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") ...

The U.S. Department of Health and Human Services Office of Inspector General (OIG) once again addressed an industry-sponsored genetic testing ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) ('AYR” or the 'Company”), a leading vertically integrated U.S. multi-state ...